Thyme Care Expands Oncology Social Work Model to Tackle Psychosocial Risks in Value-Based Cancer Care

New updates have been reported about Thyme Care.

Thyme Care has formally launched its Integrated Social Support model, restructuring its oncology navigation approach to make licensed master’s-level social workers the first line of intervention for cancer patients facing emotional, financial, or practical barriers. The initiative, which began rolling out in December 2025, is central to Thyme Care’s value-based care strategy and is positioned to improve outcomes and reduce avoidable utilization by addressing psychosocial risks from day one of a member’s journey.

The company has already built a team of more than 40 master-level oncology social workers and expects to nearly double that headcount by the end of the year, marking one of the largest social work investments in a value-based cancer care model. Every member is proactively screened at enrollment and on an ongoing basis for depression, anxiety, distress, suicidality, and social determinants such as financial toxicity, food insecurity, transportation challenges, and housing instability, with more than 82% of those who screen positive accepting support.

Thyme Care’s social work services are delivered virtually, allowing the company to scale access across geographies and embed psychosocial support into its broader tech-enabled care platform. At one partner site, proactive screening has revealed that 53% of members experience financial strain related to treatment, 22% face food insecurity, 13% have transportation barriers, and 3% confront housing instability, highlighting the scale of non-clinical issues that can derail adherence and drive higher costs.

The ISS model is powered by Thyme Care’s AI- and data-driven infrastructure, which integrates claims, clinical data, and social risk information into a dynamic acuity model that prioritizes outreach to the most vulnerable members. Within Thyme Care’s integrated platform, high-risk members completing electronic symptom surveys have seen a 30% relative risk reduction in emergency department or inpatient events, while those engaging in discharge assessments have experienced a 20% reduction in readmissions, supporting the business case for intensified psychosocial support.

The social work team is structured around two specialized roles: licensed clinical social workers focused on psycho-oncology and behavioral health, and licensed master social workers who concentrate on resolving practical barriers to care such as transportation, housing, and benefits navigation. All social workers are oncology-trained, with many holding additional certifications in palliative care, clinical supervision, and care management, reinforcing Thyme Care’s objective of embedding specialized psychosocial expertise into routine cancer care.

The ISS program includes ongoing structured screening, virtual peer support groups for patients in or recently out of active treatment, a 12-week self-guided curriculum with education and live group discussions, and short-term one-on-one interventions for crisis stabilization. Thyme Care reports that 88% of members engaging with its services feel more supported, underscoring the potential for the model to enhance patient experience metrics that are increasingly tied to financial performance in value-based contracts.

Leadership at Thyme Care frames this expansion as a deliberate shift to treat social and emotional needs as core clinical risk factors rather than ancillary services. By centering oncology social work within its navigation model and scaling it through technology, the company aims to improve quality, reduce acute-care utilization, and strengthen its position as a key enabler for payers, employers, and risk-bearing providers seeking to manage total cost of cancer care.

As Thyme Care continues to invest in social work hiring and technology, the ISS model is expected to deepen integration with oncologists and care teams nationally, enhancing the company’s differentiation in the competitive value-based oncology landscape. For stakeholders, the move signals an acceleration of Thyme Care’s strategy to monetize improved outcomes and patient experience through risk-based arrangements that reward reductions in emergency visits, readmissions, and other high-cost events.